Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Sarah Sammons, M.D.

Concepts (98)

Concepts are derived automatically from a person's publications.
The timeline below shows the dates (blue tick marks) of publications associated with Sarah Sammons's top concepts. The average publication date for each concept is shown as a red circle, illustrating changes in the primary topics that Sarah Sammons has written about over time.
Receptors, Estrogen, 4 publications between 2010 and 2022, average publication date June 2018. Receptors, Cell Surface, 2 publications between 2020 and 2020, average publication date April 2020. Tamoxifen, 2 publications between 2020 and 2020, average publication date April 2020. Aromatase Inhibitors, 4 publications between 2019 and 2023, average publication date January 2021. Breast Neoplasms, 17 publications between 2010 and 2024, average publication date February 2021. Antineoplastic Combined Chemotherapy Protocols, 6 publications between 2018 and 2023, average publication date March 2021. Receptor, ErbB-2, 14 publications between 2010 and 2024, average publication date May 2021. Brain Neoplasms, 9 publications between 2017 and 2024, average publication date June 2021. Cyclin-Dependent Kinase 4, 3 publications between 2019 and 2022, average publication date August 2021. Cyclin-Dependent Kinase 6, 3 publications between 2019 and 2022, average publication date August 2021. Aminopyridines, 1 publications between 2022 and 2022, average publication date June 2022. Benzimidazoles, 1 publications between 2022 and 2022, average publication date June 2022. Immunoconjugates, 2 publications between 2023 and 2024, average publication date August 2023.

To see the data from this visualization as text, click here.
Sammons's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (98)
Explore
_
Co-Authors (13)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.